



FreeStyle Libre / GLP-1 Analysis


28 Sept 2023

Executive Summary


- As the use of GLP-1 therapy has increased, the number of FreeStyle Libre users has continued to grow rapidly
- The number of FreeStyle Libre users who also use GLP-1 therapy has increased significantly over time
- FreeStyle Libre sensor adherence (number of days a sensor is worn) is higher for those who also use GLP-1 therapy
- GLP-1 adherence (number of days on GLP-1 therapy) is higher for those who also use FreeStyle Libre

As the use of GLP-1 therapy has increased, the number of FreeStyle Libre users has continued to grow rapidly


Total FreeStyle Libre User Base



Libre Intensive Insulin User Base^a






Libre Non-Intensive Insulin User Base^b



- a. Libre users who are Type 1 or Type 2 diabetics who inject insulin multiple times per day
- b. Libre users who are Type 2 diabetics that are basal-only insulin users or non-insulin users


Data in millions. Based on company model.

The number of FreeStyle Libre users who also use GLP-1 therapy has increased significantly over time




FreeStyle Libre adherence (number of days a sensor is worn) is higher for those who also use GLP-1 therapy

Libre Sensor Adherence Type 2 Intensives ^a




Libre Sensor Adherence Type 2 Non-Intensives ^b




- a. Type 2 intensives inject insulin multiple times per day
- b. Type 2 non-intensives include basal-only insulin users and non-insulin users

GLP-1 adherence (number of days on GLP-1 therapy) is higher for those who also use FreeStyle Libre

GLP-1 Adherence Type 2 Intensives^a



GLP-1 Adherence Type 2 Non-Intensives^b



- a. Type 2 intensives inject insulin multiple times per day
- b. Type 2 non-intensives include basal-only insulin users and non-insulin users

Benefits of Continuous Glucose Monitoring (CGM) that support use with GLP-1 therapy

- CGM is an accessible and affordable tool that can serve as a companion therapy to other diabetes treatments, including GLP-1
- CGM provides data and insights to help modify behavior in the short and long term
- CGM provides a level of accountability that drives higher therapy compliance and more durable outcomes
- CGM can support GLP-1 dose titration
- CGM increases patient safety by helping lower the risk of hypoglycemic events, which can be serious. This is especially important for GLP-1 users who also use insulin

Overview of data source

- This analysis was based on robust data sets that capture patient claims data for the entire U.S. retail pharmacy channel
- The U.S. retail pharmacy channel reflects the pharmacy insurance coverage for patients covered by Commercial insurance plans, Medicare Advantage plans, Managed Medicaid and Medicaid insurance plans. In addition, it covers other payment types such as Cash pay programs
- The U.S. retail pharmacy channel covers approximately 280 million people and represents approximately 2/3 of all FreeStyle Libre users in the U.S. today

**280 million source: <https://www.iconplc.com/solutions/technologies/symphony-health/>*



life. to the fullest.®

Abbott